Quantum BioPharma Ltd
CNSX:QNTM
Relative Value
There is not enough data to reliably calculate the relative value of QNTM.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
QNTM Competitors Multiples
Quantum BioPharma Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
Q
|
Quantum BioPharma Ltd
CNSX:QNTM
|
21.3m CAD | 0 | -0.5 | -0.9 | -0.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD | 17.6 | 56.9 | 38.1 | 40.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD | 6 | 21 | 14.7 | 18 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
284B CHF | 4.6 | 30.3 | 12.8 | 14.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD | 4.5 | 16.1 | 10.1 | 11.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.9B CHF | 5.2 | 20.3 | 12.7 | 16.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.4B GBP | 5.1 | 31.7 | 15.1 | 22.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 3.9 | 12 | 8.4 | 9.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD | 2.4 | 19.6 | 7.3 | 9.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 2.4 | 19.4 | 6.9 | 9 |